Company intelligence / Profile preview

Legend Biotech Corporation

Somerset, New Jersey, United Stateslegendbiotech.com ↗

Ownership: Public · LEGN
Employees: ~2500
Development stage: Commercial

Overview

Lead product CARVYKTI (ciltacabtagene autoleucel) was approved by FDA in February 2022 and received conditional marketing approval from European Medicines Agency in May 2022 for multiple myeloma. The company has demonstrated best-in-class efficacy in late-line multiple myeloma setting[4][7].

Therapeutic areas: Oncology
Modalities: Cell therapies (CAR-T, CAR-NK, CAR-γδ T)non-gene-editing CAR technologies
Industry: Biotech

Drug pipeline

42 assets

BCMA-CAR-T

Approved

41 more assets in the full pipeline.

Request access →

Partnerships

Janssen Biotech, Inc.Novartis

Financials

Market cap: $3.7B
Total revenue: $387.5M
Enterprise value: $3B

Beyond the preview

Go deeper on Legend Biotech Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Legend Biotech Corporation.

Explore the full profile